
Formats: [HTML](/news/2014/08/24/swiss-drugmaker-hoffmann-la-roche-agrees-to-acquire-american-drugmaker-intermune-for-8-3-billion.html)  [JSON](/news/2014/08/24/swiss-drugmaker-hoffmann-la-roche-agrees-to-acquire-american-drugmaker-intermune-for-8-3-billion.json)  [XML](/news/2014/08/24/swiss-drugmaker-hoffmann-la-roche-agrees-to-acquire-american-drugmaker-intermune-for-8-3-billion.xml)  

### [2014-08-24](/news/2014/08/24/index.md)

##### Hoffmann-La Roche
# Swiss drugmaker Hoffmann-La Roche agrees to acquire American drugmaker InterMune for $8.3 billion. 




### Sources:

1. [San Francisco Chronicle](http://www.sfgate.com/news/article/Roche-buys-Brisbane-drugmaker-InterMune-for-8-3-5709455.php)
1. [Cover Image](http://ww4.hdnux.com/photos/31/64/07/6767103/3/rawImage.jpg)

### Related:

1. [The U.S. Food and Drug Administration (FDA) approves Kadcyla, a new drug manufactured by Roche, for treating late-stage breast cancer. ](/news/2013/02/22/the-u-s-food-and-drug-administration-fda-approves-kadcyla-a-new-drug-manufactured-by-roche-for-treating-late-stage-breast-cancer.md) _Context: Hoffmann-La Roche_
2. [Cipla does not infringe a valid Roche patent on erlotinib (trade name "Tarceva") for the production of its generic cancer drug Erlocip, says the Delhi High Court. ](/news/2012/09/7/cipla-does-not-infringe-a-valid-roche-patent-on-erlotinib-trade-name-tarceva-for-the-production-of-its-generic-cancer-drug-erlocip-says.md) _Context: Hoffmann-La Roche_
